Consumer Cyclical
Dr. Martens plc(DRMTY)
Live Price
Offline$1.83
+0.00% today
1Y Change
-3.68%
Window
Jun 26, 2025 β Jun 24, 2026
- Market Cap
- $620.00M
- Revenue Growth
- -10.2%
- EPS Growth
- -92.9%
- Dividend Yield
- 4.0%
Coverage: 258 bars Β· Jun 26, 2025 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Dr. Martens plc (DRMTY) is a Consumer Cyclical stock with a market cap of $620.00M and listed on OTC. The stock last traded around $1.83 and down 3.7% across the available one-year price window (Jun 26, 2025 β Jun 24, 2026). Baseline metrics include revenue growth of -10.2%, EPS growth of -92.9%, a dividend yield of 4.0%. What stands out right now is revenue -10.2%, EPS -92.9%, free cash flow +27.3% with operating margin 9.5% and ROIC 5.9%. The dividend matters to the case here, with a current yield around 4.0%. Valuation already assumes a fairly strong business story at P/E 40.7 and price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DRMTY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Cyclical peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-10.2% vs +7.5% peer median
Operating Margin
Near sector median
+9.5% vs +8.4% peer median
P/E
Above sector median
40.7 vs 18.1 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Nov 26, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -10.2% and EPS is at -92.9%, with operating margin around 9.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Nov 26, 2025 | β | +0.0% | +0.0% | +7.4% |
2025 Jun 5, 2025 | β | +0.0% | +0.0% | +12.4% |
2025 Jan 27, 2025 | β | +0.0% | +0.0% | +12.4% |
Benchmark Edge
DRMTY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DRMTY
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DRMTY Max Drawdown
-43.62%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DRMTY and SPY.
Company Overview
Dr. Martens plc
Other OTC
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
- Leadership
- Onyeije Ogueri Nwokorie
- IPO Date
- Feb 7, 2022
- Employees
- 2.6k
- Street Address
- 28 Jamestown Road
- Mailing
- London, NW1 7BY
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 12 1415 7047
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 40.7
- EV/EBITDA
- 6.1
- Price/Sales
- 0.8
- Price/Book
- 1.9
Growth
- Revenue
- -10.2%
- EPS
- -92.9%
- Free Cash Flow
- +27.3%
Profitability
- Gross Margin
- 61.1%
- Operating Margin
- 9.5%
- Net Margin
- 1.9%
- ROE
- 4.4%
- ROIC
- 5.9%
Balance Sheet
- Debt/Equity
- 1.21
- Current Ratio
- 2.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.